The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Taiho Pharmaceutical
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Klus Pharma; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Taiho Pharmaceutical
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; IBM; Immunomedics; Inflection Biosciences; Mersana; Origimed; PACT Pharma; Pieris Pharmaceuticals; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Xencor
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Seagen; Taiho Pharmaceutical
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Debiopharm Group; Delcath Systems; Genoscience Pharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Wren Laboratories
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana; Pfizer
 
Chigusa Morizane
Honoraria - Eisai; Merck Sharp & Dohme; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Abbvie; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Eisai (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Thomas Benjamin Karasic
Research Funding - Bristol-Myers Squibb; Celgene; H3 Biomedicine; Lilly; Sirtex Medical; Syndax; Taiho Pharmaceutical
 
Thomas Adam Abrams
Stock and Other Ownership Interests - Guardant Health; InVitae; Jounce Therapeutics
Consulting or Advisory Role - Aduro Biotech; Bayer; Bristol-Myers Squibb; Eisai; Exelixis/Ipsen; Kaleido Biosciences; Merck
Research Funding - Lilly
Expert Testimony - Genentech
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nihon Servier; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Yaohua He
Employment - Taiho Pharmaceutical
 
Nital Soni
No Relationships to Disclose
 
Karim A. Benhadji
Employment - Lilly; Taiho Pharmaceutical
Stock and Other Ownership Interests - Lilly
 
John A. Bridgewater
Honoraria - Merck Serono; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER